diagnost tool
guid realli disappoint thesi
broken reiter buy rate lower pt
guid revenu street stagger shortfal
manag character guid worst-cas scenario take
larg dtc custom believ suggest may offset
later year talk manag given insight dtc
genet test space believ time issu know
impact month visibl
know exactli slower assum
dtc custom think sens go see like
today dtc test order less world
expect segment achiev least double-digit growth next three year
exclud custom time issu reiter buy trim pt
guid disappoint initi revenu guid
street midpoint ep
expect lower sale larg dtc custom know
precis detail manag indic us larg dtc custom chang
strategi indic need mani kit
go know orasur labcorp
someth go rippl effect suspect
possibl upgrad technolog enabl greater health insight
patient reduc test discount heavi tv ad spend least
vs prior year privat compani talk
employe understood benefit move valu chain exom plu
whole genom genotyp point futur
go dtc test lot last friday ny time publish scath
opinion piec clinic util test scrutini new follow
rebutt ceo publish yesterday meanwhil ilmn-spinout helix
market time inform exom plu offer dtc compani
asia wuxi nextcod experienc robust growth
lunadna look share econom databas custom certainli
much differ model furthermor genet test leader invita
announc last month offer new way patient initi test order
on-line cut clinician ubiom year
beat rev y/i beat beat
guid midpoint ep beat our/street
gm crush far exceed
molecular collect rev y/i difficult comp last year
though royalti payment ancestri come
gm beat total
materi lower estim page model commentari
price close busi februari
orasur domin provid saliva collect
devic genet test leader oral fluid
diagnost rapid point care hiv hcv test
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
model chang made big signific chang model account
yesterday updat previous model revenu
higher street bake reduct base
compani guidanc rel prior revenu estim also take
conserv view suspect like lighter
expect significantli lower revenu estim
add first time compani two recent acquisit corebiom
novosani guid net revenu dilut adj
ep ex-transact cost term number lower revenu
estim lower adj ep estim
due much lower revenu partial off-set higher level
model prior estim acknowledg
ton visibl either full-year revenu full-year gross margin
believ new estim achiev could beaten better-
than-expect revenu molecular collect particularli market share
recoup player market like ancestri helix other
note intern player like wuxi nextcod may
also see major growth beyond mention think microbiom
busi could grow close tripl digit also lower out-year revenu
ep estim rais gm outlook
pt valuat framework lower pt use
multipl revenu estim discount back two year
discount rate addit ad compani net cash posit approxim
stock price cover compani mention
laboratori corpor america hold lh -nyse hold
buy unchang target price februari
diagnost tool
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
buy unchang target price februari
diagnost tool
buy unchang target price februari
diagnost tool
buy unchang target price februari
diagnost tool
author analyst canaccord genuiti whose name appear front page research herebi certifi
recommend opinion express research accur reflect author analyst person independ
object view design invest relev issuer discuss herein within author
analyst coverag univers ii part author analyst compens directli indirectli relat
specif recommend view express author analyst research
analyst employ outsid us regist research analyst finra analyst may associ person
canaccord genuiti llc therefor may subject finra rule nyse rule restrict commun
subject compani public appear trade secur held research analyst account
individu identifi sector coverag cover subject compani industri identifi jurisdict author
analyst report
date time first dissemin februari et
date time product februari et
price target base use multipl revenu estim discount back two year
discount rate addit ad compani net cash posit approxim
pt use multipl adj ep estim
laboratori corpor america hold lh
price target lh appli multipl adj ep estim assum modest earn
per share growth project think mid-point lower end rang warrant compani expect achiev
slower top bottom line growth rel histor rang opinion
risk achiev target price valuat
regulatori risk exist new test indic delay denial approv would neg affect compani commerci risk
exist product reimburs competit continu weak economi could inhibit growth orasur drug
abus test busi risk associ intern sale infecti diseas product risk relat fund hiv
particularli unit state competit risk gener hiv product dna genotek subsidiari larg
custom failur continu work would advers impact busi
believ key risk includ major new product launch novaseq instrument premium valuat excess
peer group risk associ demand pace novaseq placement hiseq unit decommiss
competit noise/tract though believ meaning competit risk well bay nih/govern budgets/
spend particularli foreign govern like japan genom research center regulatori risk fda addit
risk factor less concern includ typic medic technolog risk price instrument consum risk
associ move test clinic increas compani focu bioinformat long-term also
highlight spend scale helix
laboratori corpor america hold lh
labcorp integr covanc macroeconom weak may threaten volum margin unemploy rate
hover around variou macroeconom headwind potenti reduc demand diagnost servic especi drugs-
of-abus doa pre-employ test rel cyclic busi segment roughli volum revenu
healthcar reform may lead medicar reimburs cut labcorp deriv revenu medicar medicaid
program lab industri provid face risk declin reimburs medicar feder govern seek
curb acceler growth rate healthcar cost believ all-in medicar reimburs rate lab increas
modestli expect medicar reimburs declin approxim labcorp face competit threat
could slow growth labcorp compet industri leader quest diagnost along numer smaller independ nich
clinic laboratori quest slightli larger scale scope labcorp smaller competitor may prove nimbl
innov labcorp australian-bas sonic healthcar build signific presenc
compet labcorp acquisit northeast lh compet bio-refer lab compani deriv
buy unchang target price februari
diagnost tool
revenu higher-margin esoter test negoti health plan plan includ manag care organ
health insur provid repres approxim compani volum revenu compani largest health
plan exclus contract end repres approxim revenu estim
labcorp compet aggress quest contract health plan larg price margin contract length
distribut rate
global stock rate
total includ stock review
buy stock expect gener risk-adjust return next month
hold stock expect gener risk-adjust return next month
sell stock expect gener neg risk-adjust return next month
rate canaccord genuiti provid research coverag relev issuer
risk-adjust return refer expect return relat amount risk associ design invest
specul stock bear significantli higher risk typic valu normal fundament criteria invest
stock may result materi loss
recommend histori date global stock rate tabl
list recommend issuer coverag dissemin preced period
may obtain follow websit provid hyperlink report read electron http //disclosures-
requir company-specif disclosur date public
